LG Chem's $1.8B Investment Fuels AVEO Oncology's Global Expansion

The October issue of OncoDaily magazine, curated by Oncology Fellow Elen Baloyan, features exclusive interviews, scientific advances, and guides related to ESMO25, highlighting significant contributions in the field of oncology. Istvan Petak from Genomate Health expressed enthusiasm about connecting with colleagues at ESMO25 and promoting their computational tools designed to personalize treatment plans and improve drug discovery in oncology. Dario Trapani launched the CONQUER study to assess how clinical oncology guidelines are applied worldwide, aiming to identify barriers and enhance evidence-based cancer care globally. The European School of Oncology (ESO) continues its mission since 1981 to provide independent, multidisciplinary training to oncology professionals worldwide, delivering extensive education and maintaining financial independence. Additionally, AVEO Oncology, now part of LG Chem, is advancing its oncology portfolio through significant R&D investments and strategic collaborations, focusing on innovative monoclonal antibody therapies, including immune checkpoint inhibitors and next-generation treatments such as antibody-drug conjugates and bispecific antibodies. These developments collectively demonstrate ongoing innovation, collaboration, and commitment to improving cancer care and outcomes globally.